RN Mobile Menu

Search form


All Content

© Lightspring/Shutterstock.com

The agent reduces cardiovascular events but has only a moderate effect on RA disease progression and activity.

© DavidSmart/Shutterstock.com

Rates of prescription filling and treatment adherence are very low in patients with new diagnoses.

© ESB Professional/Shutterstock.com

Complaints about loss of self, loss of role identity, and lower quality of life dominate within this patient population.

© Andy Dean Photography/Shutterstock.com

Associated comorbidities can bias clinical disease activity measures.

© JPC-PROD/Shutterstock.com

Many nontraumatic low intensity complaints in the general population do not reach the threshold for consultation.

© PathDoc/Shutterstock.com

The conditions often coexist, and a bidirectional association is suggested.

© ratmaner/Shutterstock.com

The incretin-insulin axis and incretin effect are disrupted in patients with RA.

© Lightspring/Shutterstock.com

This is the only fully human anti-TNF-α infused therapy approved for psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis.

© Lightspring/Shutterstock.com

Both romosozumab and calcium help fracture prevention, and most young adults have fractures at nonosteoporotic sites.

© Kateryna Kon/Shutterstock.com

Cardiovascular disease prevention and treatment strategies for patients with diabetes may apply.


By clicking Accept, you agree to become a member of the UBM Medica Community.